Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.72 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.72 |
| ▸ | ITGAV | P06756 | 9/20 | 0.72 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.57 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.57 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.45 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16883935 | 1.00 | ITGB3 (0.72) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL16883934 | 1.00 | ITGB3 (0.72) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL24433369 | 1.00 | ITGB3 (0.72) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL22194105 | 0.99 | ITGB3 (0.71) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL24433360 | 0.92 | ITGAV (0.60) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL16883930 | 0.87 | ITGB3 (0.84) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL16883928 | 0.87 | ITGB3 (0.84) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| Eptifibatide SCHEMBL22193879 | 0.83 | ITGB3 (1.00) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| Eptifibatide SCHEMBL16883987 | 0.83 | ITGB3 (1.00) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| Eptifibatide SCHEMBL29353236 | 0.83 | ITGB3 (1.00) | ITGB3ITGA2BITGAVITGB5ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044236-A1 | Integrin Antagonists | THE GENERAL HOSPITAL CORPORATION | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044236-A1 | Integrin Antagonists | ITGA5, ITGB5, ITGB3 | ITGB3 3/4885ITGA2B 7/4885ITGAV 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.